Malaria remains a very important infectious disease of the tropics and every effort is being made to control the disease. The development of drug resistance and declining efficacy against most of the antimalarial drugs/combination in current clinical practice is a big challenge for the scientific community, and in the absence of an effective vaccine, the problem becomes worse. Current consensus is that malaria elimination would only be possible if the sexual stage parasite (gametocyte) is cleared along with the asexual parasite. Presently, only a few standard anti-malarial drugs, including artemisinin and primaquine, are able to kill some sexual stage parasites while most other drugs rather promote gametocyte development. Medicines derived from plants have been used to treat a myriad of diseases in many parts of the world for centuries. A large proportion of people living in developing countries resort to herbal medicines as their primary source of treatment for both infectious and non-communicable diseases. Artemisinin, an active compound derived from the plant Artemisia annua, is a component of ACTs for malaria treatment. Many other plant products are currently used for treatment of malaria in many African countries. Extracts from many plants have been reported to have potent anti-Plasmodium activity. The research focus was to evaluate the anti-malarial potential of the extracts of three commonly used Ghanaian medicinal plants (Alchornea cordifolia, Carapa procera, Milletia zechiana), perform a bioactivity-guided fractionation of the active extracts by testing individual and combined fractions against asexual and sexual stage parasites in vitro (P. falciparum) and in vivo (P. Berghei), assess the toxicological profile and the potential immunomodulatory activities of active fractions both in vitro and in murine models.